Clinical Trials Browser

Neoplasm, Residual × Daunorubicin × 1 year × Clear all

NCT07131059 2025-08-20

MRD-positive AML Clinical Study

Phase NA Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual